Positive results for zoliflodacin, EMA approval for fexinidazole and Merck cuts rotavirus commitment – take a look a the month’s industry headlines.
The first population-level evidence has proved the rotavirus vaccination saves lives in low-income settings.
New study finds that the oral rotavirus vaccine response could be influenced by changes in the human microbiota.
Take a look at how advancements in genetic engineering has led to advances in vaccine manufacturing, with a divergence from live cell cultures to recombinant production in host cells.
Oral vaccines are less immunogenic when given to infants in low-income countries, compared with high-income countries, limiting their potential public health impact and in this review the authors evaluate the factors that might contribute to this phenomenon.
Researchers have pinpointed the four key pathogens responsible for diarrheal disease, a number one cause of morbidity among young children in sub-Saharan Africa and South Asia, highlighting the possible interventions available.